ProBiotix Health Plc (‘ProBiotix’), a life sciences company developing probiotics to support cardiometabolic health, has strengthened its global footprint with the conclusion of a commercial partnership with the Ukraine-based pharmaceutical distributor, Deutsch-Pharm Lcc (Deutsch Pharm).
This partnership will see an initial focus on the Ukrainian market followed by Uzbekistan and other countries in the region, with commercialisation expected during Q1 2025.
As part of the agreement, Deutsch-Pharm will utilise two ProBiotix products in an initial phase: YourBiotixX3, which targets cholesterol lowering, and YourBiotixVH, which targets general vascular health. Both products will be introduced under the Deutsch-Pharm brand.
Ukraine has a population of 38 million people, with a significant elderly population, in addition to a high rate of individuals suffering from cardiovascular disease.
The World Health Organisation (“WHO”) estimates that over 40% of the adult population has elevated cholesterol levels. These consumers could benefit from preventive interventions. Until recently, no natural preventative clinically documented dietary supplements have been available to consumers in Ukraine.
Steen Andersen, CEO of ProBiotix, commented, “We are excited for the opportunity to work with a leading company like Deutsch-Pharm to open up this region for our probiotic products based on LPLDL®.
“Through this significant cooperation, our products will become available to Ukrainian consumers through brick-and-mortar pharmacies as well as online stores. This offers an excellent opportunity to position products with a professional partner with an in depth understanding of the market dynamics in Ukraine. We have high aspirations for this collaboration, which we are convinced will be a springboard for further successful expansion into other adjacent countries.”
Pavlo Huzar, General Director of Deutsch-Pharm, added, “We are pleased to start this partnership with ProBiotix Health. This is another important step towards the implementation of our mission to provide consumers in Ukraine and other selected countries in the region with innovative, efficacious, and economically feasible products.
“We are increasingly building our product line, so the collaboration with ProBiotix is an important development for us. We are thrilled to have the opportunity to introduce the scientifically proven products from ProBiotix Health under our own brand. We are convinced that these products will help many people in Ukraine who are looking for a safe and effective way to solve the challenge of high cholesterol levels.”
Deutsch-Pharm is one of the leading pharmaceutical product distributors in Ukraine, working with over 9,000 customers and partners in the country, supplying products to hospitals, pharmacies, and online stores. Deutsch-Pharm works with leading players including Bufour, Ipensa, Hoffmann la Roche, and Fresenius.
For further information, please contact ProBiotix Health https://probiotixhealth.com/.